Group items tagged

the country's most significant collection of scientific and medical researchers.

This week, a program called MaRS Innovation announced the appointment of its first full-time president, Raphael (Rafi) Hofstein, a Harvard-trained, Israeli biomedical wizard who wants to bring together companies, scientists and funding under one roof to create a special alchemy of science and shekels.

Since its inception, MaRS has focused on turning big ideas into commercial projects. The difference between the two entities is that pretty much anyone with an idea or discovery could come to MaRS for support, regardless of whether they had their “eureka” moment in a state-of-the-art research lab or in their garage. MaRS Innovation, a separate endeavour with its own board of directors, only works with researchers from its 14 partner institutions, which include some of the most prestigious universities and hospitals in Canada. The goal of that project is to do the kind of work those institutions would normally try to do in-house, but on a bigger scale and, the project's backers hope, with better results.

MaRS Innovation is very much in its infancy. Officially launched last June, the project is barely a year old, and the board of directors was only announced this February. It has secured about $25-million in funding over five years to be used for commercialization of projects.

Dr. Hofstein is giving himself two to three years to roll out a success story – be it the creation of a new small company founded on the back of a researcher's drug discovery and funded by a big pharmaceutical firm, or a new discovery that, packaged properly, attracts serious venture-capital money.

The federal government has also taken notice, naming MaRS Innovation as one of 11 new “Centres of Excellence for Commercialization and Research,” a designation that came with almost $15-million in funding.

California Governor Arnold Schwarzenegger speaks at MaRs with Premier Dalton McGuinty after a tour of the building in 2007.

Indeed, the MaRS Innovation model of pushing for commercial applications of research seems to be directly in line with the philosophy of the Conservative government, which clearly favours practical results when it comes to funding for scientific research.

But those tasks involve two separate skill sets, Mr. Tabrizi suggests, and may be much better suited to a place such as MaRS, where academic and industry heavyweights converge.

Many of MaRS's biggest partners are in health care, and Dr. Hofstein is jumping in with a list of priorities that includes focusing on stem-cell research and oncology.

MaRS itself has always been good at bringing people from various sectors together, but there's no guarantee that Dr. Hofstein's plan will work, especially in the two-to-three-year timeline he mentions when talking about a rollout date for the first MaRS Innovation projects.

Indeed, Mr. Tabrizi says some Silicon Valley insiders marvel at what MaRS Innovation is trying to do. “I think there's something innovative there,” he says. “Something different is being done.”

"To make failure a learning experience, first you have to celebrate it by acknowledging in a very positive way, the person who tried something and failed. You can't hide it under a table," says Plant. "You've got to develop a system that both rewards for the attempt as well as the success. Frequently, we don't do that and that sends a bad message. The act of punishing people makes them want to stop innovating."

We also need to build more accountability into failure, according to Plant who says that when failures are detrimental to the economy, we can't pretend that nothing happened. "Right now, some people are being rewarded for absolutely hideous failures, such as in the banking system," says Plant, who is also a Chartered Management Accountant. "Part of the problem is accounting which does a very poor job of measuring risk. Never leave anything up to the accountants!"

According to Plant, there's a different risk tolerance in smaller companies versus big ones, although he doesn't see a real difference by industry. Whether a company tolerates or accepts risk depends largely on the nature of the company. "The more established companies probably don't tolerate failure as well so they don't actually incubate a culture of risk," says Plant. "Larger companies do a lot of things to make sure they don't fail. Smaller ones tend to favour risk because it's the only way they can get ahead. And if you're doing things that haven't been done before, then you're going to fail again and again."

"You have to allow people to fail in this economy," says Plant. "It's failure that leads to productivity gain and innovation."

"You need a culture that allows failure for success because without it, people become anti-failure," says Charles Plant. "Trying different things is the act of innovation. If you fail 14 times, hopefully you're going to succeed on the 15th try. Without failure, we're not going to be driving and growing the economy."

Innovation is the result of taking big leaps,

Innovation is the result of taking big leaps, but failure is often the downside of taking those leaps.